- Home
- Applications
- europe
- platelet
Show results for
Refine by
Platelet Product Applications In Europe
10 applications found
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots.https://www.bocsci.com/prasugrel-impurity-ii-cas-1391194-39-0-item-483208.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots.https://www.bocsci.com/prasugrel-impurity-iii-cas-1391194-50-5-item-483210.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots.https://www.bocsci.com/prasugrel-impurity-i-cas-1391194-45-8-item-483209.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
An impurity of Prasugrel.Prasugrel is a platelet inhibitor. It can be used to prevent formation of blood clots. ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
Now the qCell T series provides a sophisticated platform with outstanding potential to face such challenging situations due to its capability to evaluate the plasmatic pathway as well as the platelets in real time (Hussain et al, 2016; 2015; 2015; 2013). Recent developments in the field 'molecular imprinting' employing the QCM technology promise platelet aggregation sensing in real patients by synthetic biomimics in near future (Hussain, 2016). ...
By3T Analytik GmbH & Co. KG based in Neuhausen ob Eck, GERMANY
We adapted an autologous ex-vivo gene therapy method to load the patient’s own TEMs precursors, that are hematopoietic stem and progenitor cells (HSPCs), with an immunotherapeutic transgene sequence. By re-introducing gene-modified HSPCs into the patient, we seek to take advantage of the self-renewing and multi-differentiation capability of HSPCs to enable durable and potentially long-term effects following a single ...
ByGenenta Science based in Milano, ITALY
Preventative care for obstetric related venous thromboembolism (VTE). Pulmonary embolism (PE) is the leading cause of maternal death in the developed world. Patients are 5 times more likely to develop deep vein thrombosis (DVT) during pregnancy2. The UK incidence of VTE in pregnancy and the puerperium is 1–2 episodes per 1,000 patients3 and accounts for 10% of all maternal deaths in the United ...
ByFirstkind Ltd based in High Wycombe, UNITED KINGDOM
The development of laser technology extends back to the time around 1920 to Albert Einstein. After the first laser was constructed in 1960 the advances in laser technology developed in leaps and ...
ByHeltschl Medizintechnik GmbH based in Schlüsslberg, AUSTRIA
Traditionally, primary treatment for DVT has focused on anticoagulation, rather than thrombus removal. Anticoagulation therapy does not remove existing thrombus but rather prevents the propagation of the ...
BySurmodics, Inc. based in Eden Prairie, MINNESOTA (USA)
Endovascular clot removal methods can provide immediate symptom relief and, by removing clot early, physicians can identify an underlying obstructive lesion that may require a stent. Current endovascular treatment methods involve catheter-directed thrombolysis (CDT), percutaneous mechanical thrombectomy (PMT), balloon venoplasty, iliac vein stenting, and manual ...
BySurmodics, Inc. based in Eden Prairie, MINNESOTA (USA)